Taprenepag isopropyl is a highly selective agonist of the EP2 receptor.

Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and no ocular findings occur for animals in the low-dose group (0.75 mg/day) [1].

1005549-94-9

C27H28N4O5S

520.6

PF-04217329;Taprenepag isopropyl

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years